Abstract: The present disclosure belongs to the technical field of veterinary biological products, and specifically relates to a triple vaccine for diseases caused by Salmonella typhimurium, Riemerella anatipestifer and Escherichia coli. In the triple vaccine, antigens are an inactivated Salmonella typhimurium S01 strain, an inactivated Riemerella anatipestifer R01 strain and an inactivated Escherichia coli E01 strain. The three strains used in the vaccine have high virulence, disable immunogenicity and disable cross-protection. The prepared vaccine has a desirable safety, causing no local or systemic adverse reactions. In a shelf life test, all indicators of the vaccine are stable and effective after a data analysis of traits, a safety test and an efficacy test; in addition, efficacy test results prove that the inactivated triple vaccine can produce desirable antibodies and relatively desirable attacking protection.

Abstract: Disclosed are an external preparation of imidacloprid, a preparation method and use thereof, which relates to the technical field of veterinary drugs. The present disclosure uses alcohol solvent as the dispersion medium of imidacloprid technical, which can ensure the stability of imidacloprid technical; The present disclosure uses one or more of dibutyl hydroxytoluene, hydroxymethyl, propyl hydroxybenzoate and butylated hydroxyanisole as the antioxidant, which can effectively prevent the oxidation of imidacloprid technical and prolong the preservation time of external preparations of imidacloprid; The present disclosure uses one or more of propylene carbonate, povidone and copovidone as the stabilizer, which can reduce the volatility of the solvent and maintain the stability of the dispersion system. At the same time, the adjuvants used in the present disclosure have the advantages of safety, no skin irritation, low cost, and are suitable for market promotion and application.

Abstract: A veterinary bromhexine hydrochloride soluble powder, a preparation method and use thereof are disclosed. The method includes: (1) weighing a prescription amount of bromhexine hydrochloride and a part of prescription amount of citric acid, performing a primary mixing, pulverizing, sieving and dividing the mixed material into three equal parts; (2) weighing a remaining prescription amount of citric acid, pulverizing, sieving and dividing it into three equal parts; (3) weighing a prescription amount of lactose, sieving, and weighing three parts of the lactose accounting for 10% of the total amount; (4) putting one part of the mixed material obtained in “1”, one part of citric acid obtained in “2” and one part of lactose obtained in “3” alternately into a multi-directional motion mixer; (5) notifying an QA to inspect semi-finished products; and (6) packaging qualified semi-finished products, and warehousing qualified finished products.

Abstract: The present disclosure belongs to the technical field of veterinary biological products, and specifically relates to a triple vaccine for diseases caused by Salmonella typhimurium, Riemerella anatipestifer and Escherichia coli. In the triple vaccine, antigens are an inactivated Salmonella typhimurium E01 strain, an inactivated Riemerella anatipestifer R01 strain and an inactivated Escherichia coli E01 strain. The three strains used in the vaccine have high virulence, disable immunogenicity and disable cross-protection. The prepared vaccine has a desirable safety, causing no local or systemic adverse reactions. In a shelf life test, all indicators of the vaccine are stable and effective after a data analysis of traits, a safety test and an efficacy test; in addition, efficacy test results prove that the inactivated triple vaccine can produce desirable antibodies and relatively desirable attacking protection.